Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance

verfasst von: Fatemeh M. Kamazani, Gholam Reza Bahoush, Mahnaz Aghaeipour, Shahram Vaeli, Zahra Amirghofran

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The expression of CD44 and CD27 molecules correlates with the differentiation stage of B cell precursors. The present study was designed to investigate the prognostic relevance of CD44 and CD27 molecules in patients with B cell acute lymphoblastic leukemia (ALL). CD27 and CD44 expression was determined in 58 patients by flow cytometry and their relation to established prognostic factors and response to therapy was investigated. Four patterns of expression were found; CD27 single positive (SP) in 20.7 % of patients, CD44SP in 25.8 %, CD27CD44 double positive (DP) in 20.7 %, and CD27CD44 double negative (DN) in 32.8 %. CD27 expression and the CD27SP pattern correlated directly with TEL/AML1 genotype (P = 0.012). Conversely, CD44 expression and the CD44SP pattern correlated inversely with this genotype (P = 0.016). Patients with the DP pattern had a lower WBC count (P = 0.03), lower percentage of blasts in their bone marrow (P = 0.028), and higher platelet count, whereas CD44SP patients had a higher WBC count and higher percentage of bone marrow blasts. Moreover, a negative association between DN pattern and complete remission (CR) rate was detected (P = 0.03). Mean CD27 expression was significantly higher in low-risk group and in patients who achieved CR (P = 0.001), and in those with a higher platelet number (P = 0.046) and less extramedullary involvement (P = 0.008). Although survival and CR duration were longer in patients with DP pattern and shorter in those with DN pattern, the result did not reach statistical significance. The expression of CD27 together with CD44 showed a relationship with several established risk factors as well as response to therapy, indicating the biological significance of these molecules in ALL.
Literatur
1.
Zurück zum Zitat Trehan A, Cheetham T, Bailey S. Hypercalcemia in acute lymphoblastic leukemia: an overview. J Pediatr Hematol Oncol. 2009;31:424–7.PubMedCrossRef Trehan A, Cheetham T, Bailey S. Hypercalcemia in acute lymphoblastic leukemia: an overview. J Pediatr Hematol Oncol. 2009;31:424–7.PubMedCrossRef
2.
Zurück zum Zitat Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology, vol. ch. 19. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology, vol. ch. 19. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
3.
Zurück zum Zitat Pieters R. Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%. Ned Tijdschr Geneeskd. 2010;154:A1577.PubMed Pieters R. Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%. Ned Tijdschr Geneeskd. 2010;154:A1577.PubMed
4.
Zurück zum Zitat Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol. 2010;151:295–311.PubMedCrossRef Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol. 2010;151:295–311.PubMedCrossRef
5.
Zurück zum Zitat Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M. The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acutelymphoblastic leukemia. Arch Iran Med. 2011;14:170–4.PubMed Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M. The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acutelymphoblastic leukemia. Arch Iran Med. 2011;14:170–4.PubMed
6.
Zurück zum Zitat Escherich G, Horstmann MA, Zimmermann M, COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL):long-term results of trials 82, 85, 89, 92 and 97. Leukemia. 2010;24:298–308.PubMedCrossRef Escherich G, Horstmann MA, Zimmermann M, COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL):long-term results of trials 82, 85, 89, 92 and 97. Leukemia. 2010;24:298–308.PubMedCrossRef
7.
Zurück zum Zitat Amirghofran Z, Daneshbod Y, Gholijani N. Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res. 2009;17:447–54.PubMedCrossRef Amirghofran Z, Daneshbod Y, Gholijani N. Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res. 2009;17:447–54.PubMedCrossRef
8.
Zurück zum Zitat Fathi M, Amirghofran Z, Shahriari M. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol. 2012;29:2046–52.PubMedCrossRef Fathi M, Amirghofran Z, Shahriari M. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol. 2012;29:2046–52.PubMedCrossRef
9.
10.
Zurück zum Zitat Vaskova M, Fronkova E, Starkova J, Kalina T, Mejstrikova E, Hrusak O. CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens. 2008;71:57–66.PubMed Vaskova M, Fronkova E, Starkova J, Kalina T, Mejstrikova E, Hrusak O. CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens. 2008;71:57–66.PubMed
11.
Zurück zum Zitat Kobayashi M, Imamura M, Uede T, Sakurada K, Maeda S, Iwasaki H, et al. Expression of adhesion molecules on human hematopoietic progenitor cells at different maturational stages. Stem Cells. 1994;12:316–21.PubMedCrossRef Kobayashi M, Imamura M, Uede T, Sakurada K, Maeda S, Iwasaki H, et al. Expression of adhesion molecules on human hematopoietic progenitor cells at different maturational stages. Stem Cells. 1994;12:316–21.PubMedCrossRef
12.
Zurück zum Zitat Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–85.PubMedCrossRef Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–85.PubMedCrossRef
13.
Zurück zum Zitat Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, et al. High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95. Blood. 2008;112:1028–34.PubMedCrossRef Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, et al. High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95. Blood. 2008;112:1028–34.PubMedCrossRef
14.
Zurück zum Zitat Hara J, Matsuda Y, Fujisaki H, Tokimasa S, Ohta H, Osagi Y, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol. 2000;72:69–73.PubMed Hara J, Matsuda Y, Fujisaki H, Tokimasa S, Ohta H, Osagi Y, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol. 2000;72:69–73.PubMed
15.
Zurück zum Zitat Nilsson A, de Milito A, Mowafi F, Winberg G, Björk O, Wolpert EZ, et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol. 2005;33:1500–7.PubMedCrossRef Nilsson A, de Milito A, Mowafi F, Winberg G, Björk O, Wolpert EZ, et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol. 2005;33:1500–7.PubMedCrossRef
16.
Zurück zum Zitat Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20:67–82.PubMedCrossRef Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20:67–82.PubMedCrossRef
17.
Zurück zum Zitat Moschese V, Orlandi P, Di Matteo G, Chini L, Carsetti R, Di Cesare S, et al. Insight into B cell development and differentiation. Acta Paediatr Suppl. 2004;93:48–51.PubMedCrossRef Moschese V, Orlandi P, Di Matteo G, Chini L, Carsetti R, Di Cesare S, et al. Insight into B cell development and differentiation. Acta Paediatr Suppl. 2004;93:48–51.PubMedCrossRef
18.
Zurück zum Zitat Vaskova M, Mejstrikova E, Kalina T, Martinkova P, Omelka M, Trka J, et al. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. Leukemia. 2005;19:876–8.PubMedCrossRef Vaskova M, Mejstrikova E, Kalina T, Martinkova P, Omelka M, Trka J, et al. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. Leukemia. 2005;19:876–8.PubMedCrossRef
19.
Zurück zum Zitat Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer. 2003;97:105–13.PubMedCrossRef Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer. 2003;97:105–13.PubMedCrossRef
20.
Zurück zum Zitat Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef
21.
Zurück zum Zitat Taçyildiz N, Cavdar AO, Yavuz G, Gözdaşoglu S, Unal E, Ertem U, et al. S. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival. Pediatr Int. 2001;43:354–60.PubMedCrossRef Taçyildiz N, Cavdar AO, Yavuz G, Gözdaşoglu S, Unal E, Ertem U, et al. S. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival. Pediatr Int. 2001;43:354–60.PubMedCrossRef
22.
Zurück zum Zitat Oh EJ, Kahng J, Kim Y, Kim M, Lim J, Kang CS, et al. Expression of functional markers in acute lymphoblasticleukemia. Leuk Res. 2003;27:903–8.PubMedCrossRef Oh EJ, Kahng J, Kim Y, Kim M, Lim J, Kang CS, et al. Expression of functional markers in acute lymphoblasticleukemia. Leuk Res. 2003;27:903–8.PubMedCrossRef
23.
Zurück zum Zitat Mengarelli A, Zarcone D, Caruso R, Tenca C, Rana I, Pinto RM, et al. Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2001;40:625–30.PubMedCrossRef Mengarelli A, Zarcone D, Caruso R, Tenca C, Rana I, Pinto RM, et al. Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2001;40:625–30.PubMedCrossRef
24.
Zurück zum Zitat Glouchkova L, Ackermann B, Zibert A, Meisel R, Siepermann M, Janka-Schaub GE, et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol. 2009;182:718–25.PubMed Glouchkova L, Ackermann B, Zibert A, Meisel R, Siepermann M, Janka-Schaub GE, et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol. 2009;182:718–25.PubMed
25.
Zurück zum Zitat Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA. 1997;94:6346–51.PubMedCrossRef Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA. 1997;94:6346–51.PubMedCrossRef
26.
27.
Zurück zum Zitat Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–7.PubMedCrossRef Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–7.PubMedCrossRef
Metadaten
Titel
CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance
verfasst von
Fatemeh M. Kamazani
Gholam Reza Bahoush
Mahnaz Aghaeipour
Shahram Vaeli
Zahra Amirghofran
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0359-9

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.